drug_type
RELEVANT_DRUG
intervention_type
Gene-modified cellular therapy (CAR T-cell)
drug_description
Autologous gamma delta T cells engineered to express a third-generation chimeric antigen receptor targeting glypican-3 (GPC3) with co-stimulatory domains to enhance activation and tumor cell lysis.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous; local injection
drug_mechanism_of_action
Autologous gamma delta T cells are genetically engineered to express a third‑generation chimeric antigen receptor targeting glypican‑3 (GPC3). Upon binding GPC3 on tumor cells, the CAR delivers activation and co‑stimulatory signals (e.g., CD28/4‑1BB), driving gamma delta T‑cell activation, cytokine release, proliferation, and MHC‑independent cytotoxic killing of GPC3‑positive tumor cells.
drug_name
Autologous GPC3-directed CAR-γδ T cells (third-generation)
nct_id_drug_ref
NCT06196294